Answers are grounded in this paper and cite their sources.
Gene fusions are clinically relevant oncogenic drivers and therapeutic targets across multiple solid tumors. RSPO3 rearrangements have been described primarily in colorectal carcinoma and traditional serrated adenoma of the colorectum and have only rarely been reported in cholangiocarcinoma. Here, we describe a patient with perihilar cholangiocarcinoma (pCCA), Bismuth–Corlette type IV, with imaging findings suspicious for advanced/metastatic disease, harboring a PTPRK::RSPO3 fusion, together with ERBB2 p.S310F and TP53 p.I195T mutations, identified by next-generation sequencing (NGS) performed on a brush cytology specimen obtained from the primary biliary stricture during endoscopic retrograde cholangiopancreatography (ERCP). Fluorescence in situ hybridization (FISH) confirmed an RSPO3 rearrangement consistent with the NGS-identified PTPRK::RSPO3 fusion. RSPO3 fusions are known to enhance ligand-dependent WNT/β-catenin signaling in other tumor contexts, although the functional consequences of this alteration were not directly assessed in the index tumor. Exploratory analysis of RSPO3-associated transcriptional programs in a public pCCA cohort identified associations between higher RSPO3 expression and distinct transcriptional programs, most notably epithelial–mesenchymal transition (EMT), as well as global and TCF-dependent WNT signaling. These findings provide broader biological context for the molecular alteration but do not establish fusion-driven pathway activation. Together, these findings provide a case with PTPRK::RSPO3 fusion in pCCA, expand the spectrum of RSPO3 rearrangements described in biliary tract malignancies, and highlight the need for further investigation into their biological and potential therapeutic relevance.
No takes yet. Share an insight, caveat, or question.
Sayagués et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: